CA-RUBICON-CARBON
9.7.2024 15:01:29 CEST | Business Wire | Press release
Rubicon Carbon, a carbon credit management firm, today announced a new partnership with Formula E Champion and ABT CUPRA driver Lucas di Grassi to purchase carbon credits using the company’s platform. Di Grassi is the first Formula E driver to offset his carbon footprint by personally investing in carbon credits.
Di Grassi built his own Rubicon Carbon Tonne (RCT), a diversified and actively managed portfolio of carbon credits that includes carbon removal, nature-based avoidance, and industrial avoidance projects. Through RCTs, buyers reduce risk and increase optionality and price certainty.
"We are excited to support Lucas and Formula E, who share our values in building a low-carbon future," said Tom Montag, CEO of Rubicon Carbon. "This partnership perfectly aligns with our mission to innovate and lead in the fight against climate change, and we look forward to helping Lucas on his path to decarbonizing the mobility and racing industries.”
To celebrate the partnership, di Grassi’s car and helmet proudly displayed Rubicon Carbon logos at last month’s Hankook Portland E-Prix in Portland, Oregon. The collaboration between Rubicon Carbon and di Grassi exemplifies the potential of sports partnerships to drive positive environmental change.
As an activist in mobility technology and the first Formula E driver to publicly sever ties with industries that do not prioritize sustainability, di Grassi has set a precedent for how to champion environmental responsibility as a professional athlete.
Speaking on the partnership, di Grassi noted, “I am proud to be the first driver to offset all the carbon I have emitted from traveling around the world since my first Formula E race in Beijing. Working with (Rubicon Carbon CEO) Tom Montag and his entire team is the perfect partnership for me, as Rubicon Carbon is the most qualified and credible carbon credit management firm in the world. In line with the values and objectives of Formula E, I drive an electric car and have adapted my lifestyle. But still, credible carbon avoidance and removal is the only way to do the sport we love and be responsible for our environment at the same time. I would be delighted if many other athletes, not only in Formula E, would consider the same path.”
This partnership follows Rubicon’s recent investments in carbon projects across the globe, including a large-scale ecosystem restoration project in Panama in partnership with Ponterra, Microsoft, and Carbon Streaming, a 250K+ acres restoration project in South Africa led by Imperative, and a collaboration with YvY Capital to scale up carbon investments in Brazil.
For more information on Rubicon Carbon, visit the website or follow on LinkedIn.
About Lucas di Grassi:
Lucas di Grassi is a founding member of Formula E, has competed in every race up until now and is the most successful driver on the grid in terms of podium positions. He was winner of the first ever race in Beijing 2014, Champion in the 2016/2017 and teams' Champion in 2017/2018. In addition to his role as an ABT CUPRA driver, Lucas di Grassi is an entrepreneur for innovation, sustainability and electric mobility. As co-founder of Zero Summit he is organizing technology and business panels for a zero-carbon future in many countries around the world. Since 2018, Lucas di Grassi is an official United Nations Ambassador for Clean Air. Lucas di Grassi lives in Monaco together with his wife Bianca, his son Leonardo and his daughter Beatriz.
About Formula E:
As the world’s first all-electric FIA World Championship and the only sport certified net zero carbon since inception, the ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.
About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that partners with the world’s largest enterprises to help them achieve their sustainability goals while driving global decarbonization. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking decarbonization projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709047754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
